There have been no other submissions of this review or duplications of this work. There are no conflicts of interest. This manuscript is a review of already published and ethically approved research.
The therapeutic potential of the proteasome in leukaemia†
Article first published online: 6 MAR 2008
Copyright © 2008 John Wiley & Sons, Ltd.
Volume 26, Issue 2, pages 73–81, June 2008
How to Cite
McCloskey, S. M., McMullin, M. F., Walker, B. and Irvine, A. E. (2008), The therapeutic potential of the proteasome in leukaemia. Hematol. Oncol., 26: 73–81. doi: 10.1002/hon.848
- Issue published online: 28 MAY 2008
- Article first published online: 6 MAR 2008
- Manuscript Revised: 18 JAN 2008
- Manuscript Accepted: 18 JAN 2008
- Manuscript Received: 30 OCT 2007
Many cellular processes converge on the proteasome, and its key regulatory role is increasingly being recognized. Proteasome inhibition allows the manipulation of many cellular pathways including apoptotic and cell cycle mechanisms. The proteasome inhibitor bortezomib has enhanced responses in newly diagnosed patients with myeloma and provides a new line of therapy in relapsed and refractory patients. Malignant cells are more sensitive to proteasome inhibition than normal haematopoietic cells. Proteasome inhibition enhances many conventional therapies and its role in leukaemia is promising. Copyright © 2008 John Wiley & Sons, Ltd.